Form 4: Nurix CFO Hans van Houte Executes Stock Sale

Nurix Therapeutics CFO Hans van Houte sold 14,055 shares of common stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• CFO Hans van Houte sold a total of 14,055 shares of Nurix Therapeutics common stock on May 5, 2026.
• The sales were executed in two tranches: 13,473 shares at a weighted average price of $16.5756 and 582 shares at a weighted average price of $17.1751.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stock to avoid concerns about insider trading.
• Following these transactions, the reporting person retains beneficial ownership of 37,592 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted via a pre-planned 10b5-1 trading program, which is standard practice for executive financial management.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, indicating the transaction was planned in advance rather than based on non-public information.

Negatives

• The sale represents a reduction in the direct equity stake held by a key member of the executive leadership team.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's near-term valuation.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling by C-suite executives is a common practice for liquidity and diversification purposes, particularly when executed through pre-planned 10b5-1 programs, and does not necessarily reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives to manage equity holdings while maintaining regulatory compliance.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though the systematic nature of the sale mitigates concerns regarding management confidence.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Insider Trading, Form 4, CFO, Rule 10b5-1